Terms of use

Privacy

Privacy Settings

Imprint

Contact Us

Carolina Teichmann Cravo

Get in touch and send us an email.

Want to know more?

Linkedin

Facebook

Our Leadership Principles

Our Management 

Our Story

Our Services

About Redcare

Press Releases

Blog

Public Affairs

Media Downloads

Sign up

Newsroom

Patient Care

Employee Care

Planetary Care

Sustainability

Overview

Share

News

Events and Publications

Corporate Governance

Contact

Investor Relations

Our Culture

Our Departments

Jobs

FAQs

Career

No results found

About us

Careers

LinkedIn

Twitter

Redcare Pharmacy accelerates growth, expands profitability and raises full-year 2026 guidance.

Sevenum, the Netherlands, June 15, 2026. 

Redcare Pharmacy today announced preliminary trading figures for the quarter-to-date period of the second quarter of 2026, covering the first two months of the quarter. Trading came in stronger than expected, with growth accelerating versus Q1 2026 and consistent momentum throughout the period. Growth was driven by DACH Rx and non-Rx with non-Rx growth in Germany increasing from 9% in Q1 to 12% in April and 16% in May. On the back of this performance, the Company is raising its full-year 2026 guidance. 

“Our trading shows the robustness and momentum of our business, with growth across Rx and non-Rx,” said Olaf Heinrich, CEO of Redcare Pharmacy. “We continue to gain market share and improve our profitability as we improve CX and execution in general.” 

The DACH region delivered accelerated growth quarter-to-date, supported by an acceleration of non-Rx growth in Germany and continued strong momentum in Rx. In the first two months of the quarter, segment revenue increased by 21% YoY. In Germany, non-Rx growth accelerated to 14% YoY. Total Rx sales increased by 33% YoY, with Germany showing particularly strong momentum at 57% growth, an acceleration versus 55% growth achieved in Q1. 

The International segment recorded continued strong revenue growth quarter-to-date. Nearly all countries contributed to the segment's growth with 16% in April and May, consistent with 16% in Q1.  

Adjusted EBITDA margin continues to improve YoY primarily driven by the strong growth of the high margin DACH non-Rx business and more efficient marketing spend. 

Redcare Pharmacy will publish its financial results for the second quarter of 2026 and host its quarterly conference call on July 29, 2026. The Company will not issue a further trading statement ahead of this date.  

Irina Zhurba (Director, Investor Relations)

Sven Schirmer (Director, Corporate Communications)

Originally founded in 2001, Redcare Pharmacy N.V., with EUR 2.9B in revenues in 2025, is the leading online pharmacy in Europe and active in seven countries (Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland). Headquartered in the Netherlands, Redcare Pharmacy offers its over 14 million active customers more than 500,000 different healthcare-related products. Besides OTC drugs, nutritional supplements, beauty and personal care products, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands, operating as a true one-stop pharmacy. As the pharmacy of the future, Redcare stands for comprehensive pharmaceutical services for its customers – with pharmaceutical safety always being the top priority.

Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and is part of the MDAX.

Redcare Pharmacy today announced preliminary trading figures for the quarter-to-date period of the second quarter of 2026, covering the first two months of the quarter.